By Catherine Eckford (European Pharmaceutical Review)2024-02-15T16:14:38
The innovative treatment significantly increased survival in patients with malignant pleural mesothelioma, a rare, aggressive cancer, according to Phase III data from UK researchers.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-07-16T11:00:00
Sponsored by USP
2026-02-25T15:00:00
Sponsored by Particle Measuring Systems
2026-03-04T15:00:00 2026-03-04T16:00:00
Sponsored by METTLER TOLEDO
2025-10-22T14:00:00
Sponsored by Bruker
Site powered by Webvision Cloud